Nasjonalt senter for sjeldne diagnoser. Veileder: tuberøs sklerose. https://share.articulate.com/ce6CxJVqPHavhPG-YVR32 Lest 26.3.2026.
Oslo universitetssykehus. Behandling med mTor-hemmer (Votubia - everolimus) ved tuberøs sklerose. https://ehandboken.ous-hf.no/document/136599 Lest 26.3.2026.
Northrup H, Aronow ME, Bebin EM et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021; 123: 50–66. [PubMed][CrossRef]
Zöllner JP, Franz DN, Hertzberg C et al. A systematic review on the burden of illness in individuals with tuberous sclerosis complex (TSC). Orphanet J Rare Dis 2020; 15: 23. [PubMed][CrossRef]
Chu-Shore CJ, Major P, Camposano S et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010; 51: 1236–41. [PubMed][CrossRef]
Sasongko TH, Kademane K, Chai Soon Hou S et al. Rapamycin and rapalogs for tuberous sclerosis complex. Cochrane Database Syst Rev 2023; 7: CD011272. [PubMed]
Cockerell I, Christensen J, Hoei-Hansen CE et al. Effectiveness and safety of everolimus treatment in patients with tuberous sclerosis complex in real-world clinical practice. Orphanet J Rare Dis 2023; 18: 377. [PubMed][CrossRef]
Oslo universitetssykehus. Rådgivende nettverk for medisinsk oppfølging og behandling ved tuberøs sklerose. https://www.oslo-universitetssykehus.no/avdelinger/barne-og-ungdomsklinikken/avdeling-for-sjeldne-diagnoser/sjeldensenteret-hjernesykdommer/radgivende-nettverk-for-medisinsk-oppfolging-og-behandling-ved-tuberos-sklerose/ Lest 26.3.2026.
()